Promoter methylation of RASSFIA, SHP1 and SOCS1 genes in acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS).

被引：0
|
作者：
Johan, MF
Goodeve, AC
Bowen, DT
Reilly, JT
机构：
[1] Univ Sheffield, Royal Hallamshire Hosp, Acad Unit Haematol, Div Genom Med, Sheffield S10 2TN, S Yorkshire, England
[2] Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 4HN, Scotland
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2999
引用
收藏
页码：819A / 820A
页数：2
相关论文
共 50 条
  • [31] Non-myeloablative allografting for patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML).
    Taussig, DC
    Cavenagh, JD
    Davies, AJ
    Oakervee, H
    Syndercombe-Court, D
    Kelsey, SM
    Barnett, MJ
    Rohatiner, A
    Lister, A
    BLOOD, 2002, 100 (11) : 409A - 410A
  • [32] CLINICAL CHARACTERISTICS, TREATMENT AND OUTCOMES OF PATIENTS WITH THERAPY-RELATED MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKAEMIA (T-MDS/AML)
    Maung, S.
    Burke, C.
    Hayde, J.
    Desmond, R.
    McHugh, J.
    Enright, H.
    HAEMATOLOGICA, 2015, 100 : 485 - 486
  • [33] Population pharmacokinetic modelling of decitabine in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Mistry, B.
    Gibiansky, L.
    Hussein, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] CHROMOSOMAL STUDIES IN 24 PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIAS (AML) AND MYELODYSPLASTIC SYNDROMES (MDS)
    WEH, HJ
    HOFFMANN, R
    SUCIU, S
    KUSE, R
    HOSSFELD, DK
    BLUT, 1987, 55 (04): : 236 - 236
  • [35] SOCS1 methylation predicts a high risk of acute leukemic transformation in primary myelodysplastic syndrome.
    Wu, Shang-Ju
    Chou, Wen-Chien
    Yao, Ming
    Yeh, Yo-Chia
    Tien, Hwei-Fang
    BLOOD, 2006, 108 (11) : 742A - 743A
  • [36] SOCS1 and SHP1 hypermethylation in multiple myeloma: Potential implications for epigenetic activation of the Jak/STAT pathway.
    Chim, CS
    Kwong, YL
    Fung, TK
    Liang, R
    BLOOD, 2003, 102 (11) : 369B - 369B
  • [37] A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia
    Navada, Shyamala C.
    Fruchtman, Steven M.
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Petrone, Michael E.
    Zbyszewski, Patrick S.
    Holland, James F.
    Silverman, Lewis R.
    LEUKEMIA RESEARCH, 2018, 64 : 10 - 16
  • [38] Differential Methylation Pattern of ID4, SFRP1, and SHP1 between Acute Myeloid Leukemia and Chronic Myeloid Leukemia
    Uhm, Kyung-Ok
    Lee, Eun Soo
    Lee, Yun Mi
    Park, Jeong Seon
    Kim, Seok Jin
    Kim, Byung Soo
    Kim, Hyeon Soo
    Park, Sun-Hwa
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2009, 24 (03) : 493 - 497
  • [39] RUNX1/AML1 Mutants Collaborate with BMI1 in the Development of Myelodysplastic Syndromes (MDS)/Acute Myeloid Leukemia (AML) in a Mouse BMT Model.
    Harada, Hironori
    Inoue, Daichi
    Doki, Noriko
    Ding, Ye
    Harada, Yuka
    Kitamura, Toshio
    BLOOD, 2012, 120 (21)
  • [40] Clinical relevance of vascular endothelial growth factor (VEGF) receptors 1 and 2 in a acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
    Verstovsek, S
    Estey, E
    Giles, FJ
    Manshouri, T
    Beran, M
    Rogers, A
    Keating, M
    Kantarjian, H
    Albitar, M
    BLOOD, 2000, 96 (11) : 103A - 103A
12345